Profile of HIV-Infected Hispanics with Pancytopenia

International Journal of Environmental Research and Public Health

Eduardo J. Santiago-Rodríguez¹  Angel M. Mayor²  Diana M. Fernández-Santos²  Robert F. Hunter-Mellado²  Mark Edberg²  Barbara E. Hayes²  Valerie Montgomery Rice² 

[1] Retrovirus Research Center, Internal Medicine Department, School of Medicine, Universidad Central del Caribe, Bayamón, Puerto Rico 00960, USA

关键词: HIV;    Hispanics;    blood disorders;    pancytopenia;    antiretroviral treatment;    prevalence;    mortality;   

DOI  :  10.3390/ijerph13010038

来源: mdpi

【 摘 要 】

Pancytopenia is seen in late HIV infection; it is associated with medical complications and with decreased survival. We determined the prevalence of pancytopenia at baseline in a cohort of HIV-positive Hispanics living in Puerto Rico, and compared their socio-demographic, immunological and clinical characteristics. A total of 1202 patients enrolled between 2000 and 2010 were included. They were grouped according to pancytopenia status, defined by having: platelets <150,000 μL, white cell count <4000 μL, and hemoglobin <12 g/dL (women) or <13 g/dL (men). Differences were evaluated using Student’s t-test, Chi-square test and Kaplan-Meier method. The prevalence of pancytopenia was 8.7%. Patients with pancytopenia had lower BMI and lower CD4 count, as well as higher HIV viral load and higher proportions of unemployment, clinical AIDS and antiretroviral treatment (ART) use (p < 0.05). One-year mortality rate was significantly higher in patients with pancytopenia (18.1% vs. 5.1%, p < 0.001). When stratifying for ART this association persisted for patients who did not receive ART (41.4% vs. 5.2%, p < 0.001), but it was not seen in patients who received treatment (9.2% vs. 5.6%, p = 0.196). Pancytopenia was associated with elements of advanced stages of HIV. ART could reduce the mortality of HIV-patients with pancytopenia to levels comparable to patients without the disorders.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.